SOFIE CO.

DELIVERY ORDER FOR PRICING YEAR ONE ON IDC 36C25624D0046 FOR RADIOACTIVE PET TRACER ISOTOPES FOR MEDVAMC

NEURACEQ

EXERCISE OPTION 1 - AMYLOID FLORBETABEN INJECTIONS

PET/CT RADIOPHARMACEUTICALS

EXERCISING THE ORDERING PERIOD 5

PET RADIOPHAMACEUTICALS (OY2)

POSITRON EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS - FUND OY1

PET RADIOPHARMACEUTICALS FOR BUFFALO VA MEDICAL CENTER - DELIVERY ORDER 1.

PET MRI RADIOPHARMACEUTICALS

PET/CT RADIOPHARMACEUTICALS DECREASE MODIFICATION P00004

PET/CT RADIOPHARMACEUTICALS INCREASE MODIFICATION P00003

PET MRI RADIOPHARMACEUTICALS - MODIFICATION TO INCREASE QUANTITIES FOR THE PERIOD OF PERFORMANCE.

F18 PROSTATE-SPECIFIC MEMBRANE AGENT (PSMA) - OPTION YEAR 3

MOD 36C24225N0240 - PYLARIFY INCREASE 561C50105

RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT

PYLARIFY PIFLUFOLASTAT F18

RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT SOFIE (S0F-NEURACEQ)

PYLARIFY RADIO PHARM. DECREASE EXCESS FUNDS FROM PO 671A30043 FOR CLOSE OUT.

F-18 RADIOPHARMACY

NEURACEQ

RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT

FDG & NEURACEQ RADIOPHARMACEUTICALS

BASE YEAR NEURACEQ

FINAL INVOICES ADDED LATE FUNDING TO PAY FOR THOSE.

THIS IS FOR THE PURCHASE AND DELIVERY OF PYLARIFY.

PYLARIFY F-18 DCFPYL

RADIO-PHARMACEUTICALS

MODIFICATION TO ADD FUNDING TO DELIVERY ORDER FOR PET RADIOPHARMACEUTICALS.

F-18 RADIOPHARMACY

PYLARIFY DECREASE UNUSED FY24 FUNDS BRX

NEURACEQ RADIOPHARMACEUTICAL FOR POSITRON EMISSION TOMOGRAPHY SCANS

FDG & NEURACEQ RADIOPHARMACEUTICALS

RADIOPHARMACEUTICALS - MODIFICATION TO EXTEND THE END DATE. DEOB FOR EXCESS FUNDS NOT USED.

PYLARIFY F 18 INJECTION FOR PET SCAN IMAGING OF THE PROSTATE.

PET RADIOPHARMACEUTICALS FOR BUFFALO VA MEDICAL CENTER - DELIVERY ORDER 1.

PYLARIFY F-18 ISOTOPES

NEURACEQ

NEURACEQ

RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT

PET RADIOPHARMACEUTICALS

PYLARIFY DECREASE UNUSED FY24 FUNDS NOP

PET/CT RADIOPHARMACEUTICALS

"RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT.

PYLARIFY DECREASE UNUSED FY24 FUNDS NYH

PET/CT RADIOPHARMACEUTICALS

FDG & NEURACEQ RADIOPHARMACEUTICALS

PET RADIOPHAMACEUTICALS (OY1)

DIAGNOSTIC RADIOTRACER-ALZHEIMER PATIENTS

RADIOPHARMACEUTICAL NEEDED FOR PROSTATE CANCER PATIENT WITH METASTATIC LESIONS AFTER DEFINITE TREATMENT

RADIOACTIVE ISOTOPES PET TRACER - DO/TO ORDERING YEAR 2 IAW 36C25624D0046